Comparative Immunogenicity, Safety and Efficacy Profiles of four COVID-19 Vaccine types in healthy adults: Systematic Review cum Meta-analysis of Clinical Trial data
=====================================================================================================================================================================

* Si Qi Yoong
* Priyanka Bhowmik
* Debprasad Dutta

## Abstract

Four principal types of authorised COVID-19 vaccines include inactivated whole-virus vaccines, protein subunit vaccines, viral-vector vaccines and nucleic acid (mRNA and DNA) vaccines. Despite numerous Randomised Controlled Trials (RCTs), comprehensive systematic review and comparative meta-analysis have not been performed to validate the immunogenicity, safety and efficacy of COVID-19 vaccines in the healthy adult population. We aim to fulfil this unmet void. We searched for peer-reviewed articles about RCTs of the COVID-19 vaccines on healthy adults (18-64 years) available in eight major bibliographic databases (PubMed, EMBASE, Web of Science, Cochrane Library, Scopus, ScienceDirect, POPLINE, HINARI) till August 28, 2022. The Risk of Bias (RoB) was assessed using the Cochrane RoB-2. Random effects meta-analysis was conducted by pooling dichotomous outcomes using risk ratios (safety outcomes) and continuous outcomes using standardised mean differences (immunogenicity outcomes). Efficacy outcomes were summarised narratively. Moderate to high-quality evidence suggests that those receiving COVID-19 vaccines had significantly higher immune responses compared to placebo. Serious adverse events were rare, confirming that COVID-19 vaccines were safe and immunogenic for the healthy adult population. Remarkably, adverse events were the least common in inactivated vaccines, and nucleic acid vaccines were the most immunogenic. The efficacies of COVID-19 vaccines ranged from 21.9% to 95.9% in preventing COVID-19. We endorse all four types of COVID-19 vaccines for public health policy implementing taskforces. Yet, meta-analyses based on individual patient data are warranted for more extensive measurement of differential impacts of COVID-19 vaccines on different genders, ethnicities, comorbidities and types of vaccine jabbed.

Keywords
*   SARS-CoV-2 vaccines
*   Efficacy
*   COVID-19 Immunisation
*   Adverse Events Following Immunization (AEFI)
*   COVID-19 mass vaccination
*   Coronavirus vaccine data synthesis

## 1. Introduction

The Coronavirus Disease 2019 (COVID-19) is an infectious respiratory communicable disease caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), originating in Wuhan, China, in early December 2019 [1]. World Health Organization (WHO) announced the outbreak as a global pandemic on March 11, 2020 [2]. COVID-19 is a systemic disease with both short-, intermediate- and long-term physical and mental health impacts [3, 4]. Majority of patients experience mild to moderate symptoms and 5–10% suffer from severe or debilitating disease. Therefore, the development of effective and safe vaccines and novel therapeutics is deemed a global exigency [5].

SARS-CoV-2 belongs to the genus *Betacoronavirus* under the *Coronaviridae* family and has four primary structural proteins, viz. Spike (S), Membrane (M) and Envelope (E) proteins in the viral surface, and Nucleocapsid (N) protein in the ribonucleoprotein core [6]. S proteins bind with a host cell receptor, angiotensin-converting enzyme 2 (ACE2), which is extensively expressed in pulmonary alveolar cells, cardiac myocytes, vascular endothelium and various other cell types, leading to viral invasion [7]. Most COVID-19 vaccines innovated so far have targeted the S protein. S protein consists of a membrane-distal S1 moiety and a membrane-proximal S2 moiety and presents on the viral envelope as a homotrimer (S1-S2 and S2′). The S1 subunit facilitates ACE2 recognition via its receptor-binding domain (RBD), whereas the S2 subunit enables membrane fusion during viral entry [8].

Four major types of COVID-19 vaccines are in clinical trials and/or have received emergency use authorisation globally: inactivated whole-virus vaccines, protein subunit vaccines, viral vector vaccines and nucleic acid (mRNA and DNA) vaccines. Inactivated whole-virus vaccine candidates contain attenuated SARS-CoV-2 viruses that induce immune responses similar to their real counterparts without causing disease. Protein subunit vaccines contain antigenic parts of the SARS-CoV-2 virus rather than the whole virus to trigger an immune response. Viral vector vaccines utilise modified viruses such as adenoviruses to deliver antigen-encoding genes which encode the surface spike proteins found on the virus and are delivered into human cells. Nucleic acid vaccines contain viral genetic material to provide immunity against the virus particles by encoding the viral antigen [9]. Vaccines offer protection against COVID-19 disease by eliciting both humoral and cellular immune responses [10], which work synergistically to ultimately induce neutralising antibodies crucial for virus clearance by targeting the S protein, thus preventing infection and risk reduction of severe COVID-19 disease [6, 11].

Meta-analyses on immunogenicity, safety and efficacy of COVID-19 vaccine trials among adults published till date have pooled trial data without differentiating between age groups and accounting for comorbidities [12–15], although these covariates markedly influence vaccine efficacy and immune response. With the rapid development of COVID-19 vaccine candidates, clinicians, policymakers and the public at large experienced confusion in deciding which vaccines/vaccine type would be more effective and which would be safer. A multitude of meta-analyses focused on patient groups with various comorbidities and in the younger population [16–20]. To the best of our knowledge, no meta-analysis has been conducted on the effects of COVID-19 vaccines in the healthy adult population. Due to the rapid development and publication of COVID-19 vaccine trial data, an updated systematic review and meta-analysis is needed. Hence, the current systematic review and meta-analysis aimed to compare the immunogenicity, safety, and efficacy of different types of COVID-19 vaccines in healthy adults.

## 2. Methods

We reported this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [21]. The protocol was registered on PROSPERO (CRD42022314578).

### 2.1. Study selection criteria

We included peer-reviewed studies evaluating COVID-19 vaccine candidates irrespective of language and publication date. They must be randomised controlled trials (RCT) (Phase I-IV). Preclinical studies, and those of other study designs (e.g., quasi-experimental, reviews, opinion articles), publication types (e.g., conference abstracts, letters to editor etc.) and non-peer-reviewed articles (e.g., preprints, grey literature) were excluded.

Participants who were non-pregnant, non-lactating, healthy adults (18-64 years old) were included. When RCTs reported data on mixed populations, e.g., those with comorbidities or adults aged 65 years and above, we extracted data concerning only the subgroups of interest to our review. We excluded the trial if less than 90% of participants met the inclusion criteria (e.g., studies which mainly recruited participants aged <18 and >64 years old, >10% of participants had comorbidities which put them at risk of severe COVID-19 infection or immunosuppression, e.g., cancer, uncontrolled diabetes, cardiovascular disease, obesity). Given many vaccines are under development, this review focused on vaccines with potential clinical applicability; hence vaccines which ceased further development, or Phase I trials with very small sample sizes (with less than 20 participants in the intervention arm) were excluded unless the vaccine had been investigated in further trials.

In terms of intervention, all four types of COVID-19 vaccine candidates at any RCT phase (nucleic acid, viral vector, inactivated virus, and protein subunit vaccines) were eligible. Comparators were as defined by trials, which included placebo (e.g., saline, vaccine adjuvant or vaccine protecting for other diseases such as meningococcal conjugate vaccine) or no vaccine. However, studies on co-administering different vaccines were excluded, e.g., a COVID-19 vaccine and influenza vaccine.

Studies which evaluated at least one outcome (immunogenicity, safety and/or efficacy) were included in the review. Immunogenicity outcomes included humoral immunity [(geometric mean titres (GMT) and 95% confidence interval (CI)] of anti-RBD IgG, anti-S protein IgG and neutralising antibodies) and cell-mediated immunity (T-cell response). Safety outcomes of COVID-19 vaccine candidates included any adverse events, local, systemic, and serious adverse events. Efficacy outcomes included the number of COVID-19 infections, hospitalisations, ICU admissions, severe illness, and deaths due to COVID-19.

### 2.2. Search strategy

The detailed search strategy is presented in Supplementary File 1. We systematically searched 8 principal databases (PubMed, EMBASE, Web of Science, Cochrane Library, Scopus, ScienceDirect, POPLINE, HINARI) using keywords such as ‘safety’, ‘immunity’, ‘vaccine efficacy’ and “covid 19 vaccine’ for eligible articles on 18-19 April 2022. We also hand-searched the New England Journal of Medicine for relevant articles, as many COVID-19 vaccine RCTs were published in this journal. We searched trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform) to ensure that all relevant published studies were included. Finally, reference lists of relevant studies and reviews were assessed. Initial search results were uploaded into EndNote X20, where duplicates were removed automatically and manually. Screening of titles and abstracts was done by PB and SQY using Rayyan ([http://rayyan.qcri.org](http://rayyan.qcri.org)). They then independently assessed full texts for eligibility. Discrepancies were discussed until a consensus was reached. Given the rapid publication of COVID-19 vaccine trials, we checked regularly for peer-reviewed articles for relevant articles. The final cutoff date for inclusion into the review was August 28, 2022.

### 2.3. Data extraction

Data were extracted using a pre-piloted data extraction sheet by SQY and PB. Discrepancies were discussed until a consensus was reached. Information extracted includes author, year, country, study design, participant characteristics, vaccine characteristics, type of placebo, immunogenicity, safety, and efficacy outcomes.

### 2.4. Quality appraisal

Risk of bias (ROB) was independently assessed by PB and SQY for each study using the Revised Risk of Bias tool, and discrepancies were discussed until a consensus was reached [22]. ROB was assessed using 5 domains (bias arising from randomisation process, deviations from intended interventions, missing outcome data, outcome measurement, selection of reported results), and each domain was rated as ‘low risk of bias’, ‘high risk of bias’, or ‘some concerns’. We assessed deviations from interventions based on the effect of assignment to intervention (the intention-to-treat effect). Overall ROB for each study was evaluated accordingly, and ratings were visualised using Robvis [23].

The overall quality of evidence was rated following Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines and justifications were provided in Evidence Profile tables generated using GRADEproGDT software [24].

### 2.5. Synthesis approach

Meta-analyses were performed using Review Manager Version 5.4.1. The random-effects model was used for all analyses as it accounts for between-study heterogeneity. Meta-analysis was conducted only at timepoints which were investigated by 3 or more studies. For immunogenicity outcomes, standardised mean differences (SMD) of log-transformed geometric mean titers were selected as different assays were used, and that meta-analysis of skewed data can be performed using a natural log transformation [25, 26]. When geometric median titers were reported, we transformed them into geometric means using established formulas if possible [27]. For safety and efficacy outcomes, dichotomous data were pooled using risk ratios (RR) as the effect size. When meta-analysis was not possible (e.g., dissimilar outcomes, timepoints, inadequate data for meta-analysis, only descriptive/graphical data available), outcomes were summarised narratively.

Cochran’s Q test and I² statistics were used to evaluate heterogeneity. Statistically significant heterogeneity was set at p < 0.10. Heterogeneity was unimportant when I² = 0–40%, moderate when I² = 30–60%, substantial when I² = 50–90% and considerable when I² = 75–100%. If there were more than 10 studies in a meta-analysis and significant heterogeneity was found, subgroup and sensitivity analysis were used to investigate sources of heterogeneity [26]. We predefined subgroups to be based on age, sex and vaccine type (nucleic acid, viral vector, inactivated virus and protein subunit vaccines). There was a significant subgroup difference when p < 0.10 [28]. Sensitivity analysis was done by excluding each study. If results remain consistent, they were construed as robust. When results differed, they were treated with caution. If there were more than 10 studies in a meta-analysis, publication bias was assessed using visual inspection of funnel-plot asymmetry, Begg’s and Egger’s test [26] using Jamovi version 1.6.

## 3. Results

### 3.1. Search findings

The initial search yielded 20482 articles. After the removal of duplicates, 13112 articles were screened using titles and abstracts. Full texts of 113 articles were assessed, and finally, 41 RCTs were included in the systematic review [29–69]. The PRISMA diagram is shown in Figure 1.

![Fig 1.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F1.medium.gif)

[Fig 1.](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F1)

Fig 1. 
PRISMA diagram showing study selection process.

### 3.2. Characteristics of included studies

Studies were published from 2020 to 2022 across 25 countries, most commonly in China (n = 14), US (n = 8) and Japan (n = 5) (Table 1). Forty-one studies on 26 vaccines were included, of which 14 studies were on protein subunit vaccines, 12 on inactivated vaccines, 9 on viral vector vaccines and 6 on nucleic acid vaccines. Most were phase 1-2 RCTs, and there were 6 phase 3 RCTs [35, 42, 47, 54, 57, 65]. There was a total of 118 377 participants, with sample sizes ranging from 15 to 37594.

View this table:
[Table 1.](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/T1)

Table 1. Characteristics of included studies

### 3.3. Risk of bias

Most studies had some concerns (n = 31) with high ROB, while the rest had low ROB (n = 15). We rated the studies according to the RCT phase if possible; hence the total number does not add up to 41. Studies were rated with some concerns commonly due to the lack of information on allocation sequence concealment, and some studies did not specify the method of randomisation (Figure 2).

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F2/graphic-12.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F2/graphic-12)

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F2/graphic-13.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F2/graphic-13)

Fig 2. 
(a) Risk of bias rating for each study and (b) risk of bias rating for each domain across all studies.

### 3.4. GRADE assessment

Of the 16 outcomes assessed in the meta-analyses, 14 had moderate or high certainty of evidence. Certainty of evidence was downgraded most commonly due to high heterogeneity (inconsistency) and/or insignificant effect sizes (imprecision), and some outcomes were upgraded due to large effect sizes. The detailed GRADE assessment for each outcome is presented in Supplementary File 2.

### 3.5. Synthesis findings

Subgroup analysis was conducted based on vaccine type only, as age and sex were not possible due to inadequate information reported. Unless otherwise specified, sensitivity analysis confirmed the robustness of the results as the significance of the effect size remained unchanged.

#### 3.5.1. Immunogenicity outcomes

Cellular immune responses to COVID-19 vaccines are summarised in Table 2. All immunogenicity outcomes in the following meta-analyses refer to the number of days after the completion of the primary vaccine series (either two or three doses).

View this table:
[Table 2.](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/T2)

Table 2. Cellular immune responses of different COVID-19 vaccines

##### 3.5.1.1. Neutralising antibodies (live virus neutralisation)

Four studies reported neutralising antibody levels at 7 days after vaccination (n = 281) [34, 38, 44, 67], which was significantly higher in the vaccinated group compared to the control group (SMD = 2.51, 95% CI 1.58-3.44, p < 0.00001). Heterogeneity was considerable (I² = 84%, p = 0.0004) (Figure 3a).

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F3/graphic-17.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F3/graphic-17)

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F3/graphic-18.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F3/graphic-18)

Fig. 3 
(a) Forest plot for meta-analysis of log-transformed neutralising antibody levels 7 days after COVID-19 vaccination (measured using live virus neutralisation assays). (b) Forest plot for meta-analysis of log-transformed neutralising antibody levels 14 days after COVID-19 vaccination (measured using live virus neutralisation assays). (c) Forest plot for meta-analysis of log-transformed neutralising antibody levels 28 days after COVID-19 vaccination (measured using live virus neutralisation assays). (d) Forest plot for meta-analysis of log-transformed neutralising antibody levels 28 days after COVID-19 vaccination (measured using pseudo-neutralising antibody assays)

At 14 days after vaccination (n = 1409, 11 studies) [29–31, 34, 38, 39, 43, 45, 46, 67, 68], neutralising antibodies were significantly higher in the vaccinated group than in the control group (SMD = 4.30, 95% CI 3.54-5.07, p < 0.00001). Heterogeneity was also considerable (I² = 94%, p < 0.00001), and there was a significant subgroup difference (I² = 80.2%, p = 0.02). Protein subunit vaccines induced higher levels of neutralising antibodies (SMD = 5.01, 95% CI 4.10-5.92, p < 0.00001) than inactivated vaccines (SMD = 3.39, 95% CI 2.30-4.47, p < 0.00001) (Figure 3b). Publication bias is likely as both Begg’s (p = 0.007) and Egger’s test (p < 0.001) were significant (Supplementary File 3 Figure S1)

At 28 days after vaccination (n = 1494, 8 studies) [30, 38, 45, 46, 58, 63, 64, 68], neutralising antibodies were significantly higher in the vaccinated group than in the control group (SMD = 4.70, 95% CI 3.55-5.85, p < 0.00001). Heterogeneity was considerable (I² = 97%, p < 0.00001) (Figure 3c).

##### 3.5.1.2. Neutralising antibodies (pseudovirus neutralisation)

Five studies reported neutralising antibodies at 28 days after vaccination [38, 45, 58, 59, 69], which was significantly higher in the vaccinated group than the control group (SMD = 3.41, 95% CI 2.48-4.34, p < 0.00001). Heterogeneity was considerable (I² = 91%, p < 0.00001) (Figure 3d).

##### 3.5.1.3. Anti-RBD IgG

Log-transformed anti-RBD IgG levels 14 days after vaccination (n = 1130, 8 studies) [34, 43–46, 58, 67, 69] were also significantly higher in the vaccinated group compared to the control group (SMD = 5.68, 95% CI 3.95-7.42, p < 0.00001) with considerable heterogeneity (I² = 99%, p < 0.00001) (Figure 4a).

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F4/graphic-19.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F4/graphic-19)

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F4/graphic-20.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F4/graphic-20)

Fig. 4 
(a) Forest plot for meta-analysis of log-transformed anti-RBD IgG levels 14 days after COVID-19 vaccination. (b) Forest plot for meta-analysis of log-transformed anti-S IgG levels 14 days after COVID-19 vaccination. (c) Forest plot for meta-analysis of log-transformed anti-S IgG levels 7 days after COVID-19 vaccination. (d) Forest plot for meta-analysis of log-transformed anti-RBD IgG levels 28 days after COVID-19 vaccination

Log-transformed anti-RBD IgG levels 28 days after vaccination (n = 2326, 8 studies) [36, 38, 46, 49, 56, 58, 59, 69] was also significantly higher in the vaccinated group compared to the control group (SMD = 4.31, 95% CI 3.21-5.42, p < 0.00001). Heterogeneity was considerable (I² = 98%, p < 0.00001) (Figure 4b).

##### 3.5.1.4. Anti-S IgG

Three studies reported anti-S IgG levels at 7 days after vaccination (n = 198) [29, 39, 44], and anti-S IgG levels were significantly higher in the vaccinated group than the control group (SMD = 3.71, 95% CI 1.01-6.42, p = 0.007) with considerable heterogeneity (I² = 96%, p < 0.00001) (Figure 4c).

At 14 days after vaccination (n = 2006, 9 studies) [29–31, 43, 44, 51, 56, 63, 64], pooled SMD for anti-S IgG levels was 5.48 (95% CI 3.66-7.29, p < 0.00001) with considerable heterogeneity (I² = 99%, p < 0.00001) (Figure 4d).

#### 3.5.2 Safety outcomes

##### 3.5.2.1. Seven days after the first dose

Twelve studies reporting local adverse events seven days after the first dose of a COVID-19 vaccine were included in the meta-analysis (n = 1301) [31–33, 37, 39, 43, 44, 49, 51, 55, 64, 67], and those in the vaccine arm had a significantly higher risk of local adverse events compared to the control (pooled RR = 2.88, 95% CI 1.78-4.67, p < 0.0001). Heterogeneity was substantial (I² = 71%, p < 0.00001). There was a significant subgroup difference based on vaccine type (p = 0.03, I² = 65.7%), and only the inactivated vaccines subgroup showed an insignificant pooled RR of 1.43 (95% CI 0.60-3.41, p = 0.42), indicating that risk of local adverse events was similar between vaccine and control groups (Figure 5a). Publication bias is unlikely as Egger’s regression (p = 0.471) and Begg’s test (p = 0.638) were insignificant (Supplementary File 3 Figure S2). When the article by Mohraz et al. [44] was excluded during sensitivity analysis, heterogeneity became insignificant (I² = 17%, p = 0.28).

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F5/graphic-21.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F5/graphic-21)

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F5/graphic-22.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F5/graphic-22)

Fig. 5 
(a) Forest plot for meta-analysis of local adverse events after 7 days of the first COVID-19 vaccine dose. (b) Forest plot for meta-analysis of systemic adverse events after 7 days of first COVID-19 vaccine dose.

Ten studies reporting systemic adverse events seven days after the first dose of a COVID-19 vaccine were pooled (n = 1144) [31, 32, 37, 43, 44, 49, 51, 55, 64, 67], and the risk of systemic adverse events was similar between vaccine and control groups (pooled RR = 1.30, 95% CI 0.89-1.91, p = 0.17). Heterogeneity was substantial (I² = 63%, p = 0.004). There was also a significant subgroup difference based on vaccine type (p = 0.03, I² = 67.8%) (Figure 5b). Publication bias is unlikely as Egger’s regression (p = 0.452) and Begg’s test (p = 0.484) were insignificant (Supplementary File 3 Figure S3).

##### 3.5.2.1. Seven days after the second dose

Ten studies reporting local adverse events seven days after the second dose of a COVID-19 vaccine were pooled (n = 1193) [31–33, 37, 39, 43, 44, 55, 64, 67]. Similarly, RR was higher in the vaccine group (pooled RR = 2.61, 95% CI 1.38-4.90, p = 0.003), and heterogeneity is considerable (I² = 80%, p < 0.00001). A significant subgroup difference was found (p = 0.0003, I² = 84.2%), with only inactivated vaccines reporting an insignificant effect size (pooled RR = 1.05, 95% CI 0.48-2.28, p = 0.90) (Figure 6a). Publication bias is unlikely as Egger’s regression (p = 0.608) and Begg’s test (p = 0.862) were insignificant (Supplementary File 3 Figure S4).

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F6/graphic-23.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F6/graphic-23)

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F6/graphic-24.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F6/graphic-24)

Fig. 6 
(a) Forest plot for meta-analysis of local adverse events after 7 days of the second COVID-19 vaccine dose. (b) Forest plot for meta-analysis of systemic adverse events after 7 days of the second COVID-19 vaccine dose.

Seven studies reported systemic adverse events seven days after the second dose of a COVID-19 vaccine (n = 1005) [31, 32, 37, 43, 55, 64, 67], and the risk ratio was higher in the vaccinated group (pooled RR = 2.24, 95% CI 1.61-3.11, p < 0.00001). Heterogeneity was insignificant (I² = 35%, p = 0.16) (Figure 6b).

##### 3.5.2.2. One month after the first dose

Six studies reporting any adverse events 1 month after the first dose were pooled (n = 397) [29, 32–34, 44, 67], and there were no significant differences between groups receiving vaccine or control (pooled RR = 1.04, 95% CI 0.66-1.65, p = 0.87). Heterogeneity was moderate (I² = 48%, p = 0.09) (Figure 7a).

![Fig. 7](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F7.medium.gif)

[Fig. 7](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F7)

Fig. 7 
(a) Forest plot for meta-analysis of any adverse events after 1 month of the first COVID-19 vaccine dose. (b) Forest plot for meta-analysis of any adverse events after 1 month of the second COVID-19 vaccine dose.

##### 3.5.2.3. One month after the second dose

Seven studies reporting any adverse events 1 month after the second dose were pooled (n = 529) [32–34, 44, 61, 62, 67], and there were also no significant differences between the groups receiving vaccine or control (pooled RR = 1.20, 95% CI 0.63-1.73, p = 0.34). Heterogeneity was insignificant (I² = 0%, p = 0.89) (Figure 7b).

##### 3.5.2.4. Overall adverse events

Eight studies reported overall adverse events after 7 days (n = 1603) [38, 40, 41, 50, 52, 63, 66, 68], and the risk of adverse events was significantly higher in the vaccinated group (pooled RR = 1.68, 95% CI 1.21-2.34, p = 0.002). Heterogeneity was substantial (I² = 70%, p = 0.0001) (Figure 8a).

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F8/graphic-26.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F8/graphic-26)

![](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/08/12/2023.08.10.23293964/F8/graphic-27.medium.gif)

[](http://medrxiv.org/content/early/2023/08/12/2023.08.10.23293964/F8/graphic-27)

Fig. 8 
(a) Forest plot for meta-analysis for overall adverse events within 7 days post COVID-19 vaccination. (b) Forest plot for meta-analysis for overall adverse events within 1 month post COVID-19 vaccination

Nine studies reported overall adverse events after 1 month (n = 2235) [38, 40, 41, 45, 46, 50, 55, 59, 68], and the risk of adverse events was significantly higher in the vaccinated group (pooled RR = 1.19, 95% CI 1.01-1.40, p = 0.04). Heterogeneity was insignificant (I² = 26%, p = 0.17) (Figure 8b).

##### 3.5.2.5 Serious adverse events

Serious adverse events, defined as Grade 3 or worse, were reported in 19 studies [29, 31, 35, 40, 42, 44, 48, 52, 54–57, 59, 60, 63–67]. However, they were rare, and many studies did not specify if these were related to the vaccine. Nonetheless, the studies concluded that the vaccines had an acceptable safety profile.

#### 3.5.3. Efficacy outcomes

Efficacy outcomes were summarised in Table 1, and 6 studies reported efficacy outcomes [35, 42, 47, 54, 57, 65] ranging from 21.9% (95% CI −49.9 to 59.8) against mild-moderate COVID-19 [57] to 95.9% in preventing COVID-19 [65]. However, they were based on previous circulating variants of concern; hence the findings would not be representative of its efficacy in the current COVID-19 situation in which Omicron is the predominant strain, with subvariants such as BA.4 and BA.5 making up most of the world’s COVID-19 cases [70].

## 4. Discussions

This systematic review and meta-analysis found that the vaccinated individuals had significantly immunogenic to COVID-19 compared to the placebo. Although our meta-analyses confirmed that vaccines induce significantly higher immune responses compared to placebo up to 28 days after completion of the primary vaccination series, this does not necessarily correlate with better disease outcomes [6]. Efficacy outcomes in healthy adults, which were rarely reported in this review, should still be relied upon to assess the clinical utility of a vaccine.

COVID-19 vaccines in healthy adults, as assessed in this review, were relatively safe with minimal serious adverse events, which is consistent with previous large-scale observational studies and reviews [71–74] . Subgroup analyses suggest that inactivated vaccines may result in the lowest risk of adverse events among the four major vaccine genres. Similar incidences of adverse events concur with other observational studies as well [75, 76]. Due to misinformation, there is significant vaccine hesitancy worldwide. This review provides empirical evidence that vaccines are usually safe, countering the misconception-led vaccine hesitancy [77].

All meta-analyses conducted in this review found that immune responses (neutralising antibodies, anti-RBD and anti-S IgG) were significantly higher than the placebo group after vaccination. However, these measures may not all contribute to establishing immunity to COVID-19 infection and reducing the severity of COVID-19 disease [11]. Nonetheless, neutralising antibody levels are predictive of their protective efficacy, and we found that neutralising antibody levels were the highest in the nucleic acid vaccines subgroup (Figure 4D), which correlates to their high efficacy in preventing COVID-19 infection, as established by previous studies [11, 78]. In the context of the current COVID-19 pandemic, it was found that neutralising antibody levels were reduced by at least 1/10th against the Omicron variant compared to the original strain [11]. Hence, the findings of this outcome should be interpreted with caution as most included studies were conducted when previous strains, such as the Alpha, Beta and Delta strains were more prevalent [79]. Immune responses and actual protection against COVID-19 infection and severe disease would thus be lower in real-world conditions. A large-scale observational study found that homologous primary vaccination with 2 doses of ChAdOx1 nCoV-19, BNT162b2 or mRNA-1273 resulted in vaccine effectiveness of 48.9% (95% CI 39.2 to 57.1), 65.5% (95% CI 63.9-67.0) and 75.1% (95% CI 70.8 to 78.7) respectively at 2-4 weeks against symptomatic disease against the Omicron variant [80].

We have also descriptively summarised the cellular immune responses of COVID-19 vaccines in Table 2, which shows that they predominantly induce a Th1-mediated immune response. Studies included in the review utilised a variety of assays and outcomes; hence meta-analysis was not possible. A recent study performing head-to-head comparisons of the immune responses of those receiving mRNA-1273, BNT162b2, Ad26.COV2.S or NVX-CoV2373 vaccines found that while antibody titers declined over 6 months, memory T cells and B cells were comparatively stable, suggesting that immune memory from vaccination remains intact [81]. T-cell responses also remain robust against the Omicron variant [82], suggesting that while vaccinations may be less effective in preventing infection due to less neutralising antibodies generated against emerging variants, they are still paramount in reducing disease severity through SARS-CoV-2 specific T cells facilitating early recognition of COVID-19 virus and mediating antiviral responses [83]. Recent COVID-19 vaccine research has thus focused on the effectiveness of heterologous and homologous boosters to make up for the natural decay of antibody levels over time [84].

To the best of our knowledge, this is the first systematic review and meta-analysis that focuses on the effects of COVID-19 vaccines in the healthy adult population and provides comprehensive evidence that current vaccines are safe and immunogenic in the healthy adult population, unlike early meta-analyses on COVID-19 vaccines which had pooled outcomes without accounting for the differences in participant characteristics between studies. In addition, we have included the most recent RCTs which were not included in the latest meta-analyses published [85, 86].

However, our review was not devoid of limitations. First, numerous studies could not be included in the review or be pooled in the meta-analysis as they did not provide subgroup analyses of the RCT results on the healthy adult population. Our meta-analyses thus had relatively small sample sizes, with most included studies being Phase 1 or 2 trials where sample sizes are smaller. Our subgroup analyses should be interpreted with caution as there was an uneven distribution of studies in each subgroup [28]. Second, we only included English language studies and could have missed out on studies in other languages. Third, due to the varied outcomes investigated and poor reporting of information by some studies, some findings could not be included in the meta-analyses (e.g., no 95% CI reported, different timepoints for outcome measurement).

## 5. Conclusions

Overall, this systematic review and meta-analysis show that COVID-19 vaccines are safe and immunogenic in the healthy adult population. Future individual patient data-driven meta-analyses should be conducted to fully utilise the available RCT data and provide a more comprehensive analysis of the effects of COVID-19 vaccines according to different patient characteristics (e.g., gender, ethnicities, comorbidities). Thorough longitudinal designs calibrating exposure to SARS-CoV-2 vaccine-mediated adaptive immunity in relation to the consequential long-term advantageous and detrimental impact on diverse ethnic populations can assist in refurbishing preemptive policies against the future occurrence and outbreak of COVID-19.

## Supporting information

Supplementary File 1. Search strategy [[supplements/293964_file02.pdf]](pending:yes)

Supplementary File 2. GRADE evidence profile [[supplements/293964_file03.pdf]](pending:yes)

Supplementary File 3. Supplementary meta-analysis figures [[supplements/293964_file04.pdf]](pending:yes)

## Data Availability

This is meta-analysis and the collated dataset analysed in the present article are available upon reasonable request to the authors. 

## Declarations

### Funding

No funding was received from any public, private or non-profit agencies for conducting this systematic review and meta-analysis.

### Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Ethics approval

This is a systematic review and meta-analysis using publicly available data from peer-reviewed articles reposited in bibliographic databases; hence, no ethical approval is needed.

### Author contributions

All authors attest that they meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship. Si Qi Yoong: Methodology, Formal analysis, Investigation, Writing – original draft, Writing – review & editing, Visualisation. Priyanka Bhowmik: Conceptualisation, Investigation, Writing – review & editing. Debprasad Dutta: Conceptualisation, Writing – review & editing, Supervision.

## Acknowledgements

We would like to thank Ms Zeng Bentuo for her assistance in searching for relevant articles and Dr Liliya Eugenevna Ziganshina for her valuable advice regarding the scoping of this review.

## Footnotes

*   Email: ysq{at}nus.edu.sg

*   Email: priyankabhowmik96{at}gmail.com

*   Email: debprasad{at}ms-mf.org

*   Email: debdutta.bio{at}gmail.com

*   Received August 10, 2023.
*   Revision received August 10, 2023.
*   Accepted August 12, 2023.


*   © 2023, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)

## **References**

1.  [1].Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2001017&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

2.  [2].World Health Organisation. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020, [https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19](https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19) 11-march-2020 (2020, accessed 1 September 2022).
    
    

3.  [3].Dutta D. Neurological Impact of Covid-19 Pandemic: Lessons & Cautions. COVID-19 Pandemic Update 2020; 73–83.
    
    

4.  [4].Walia N, Lat JO, Tariq R, et al. Post-acute sequelae of COVID-19 and the mental health implications. Discov Craiova Rom 2021; 9: e140.
    
    

5.  [5].Terpos E, Trougakos IP, Karalis V, et al. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells 2021; 10: 1942.
    
    

6.  [6].Pang NY-L, Pang AS-R, Chow VT, et al. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res 2021; 8: 47.
    
    

7.  [7].Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 2021; 40: 905–919.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10096-020-04138-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33389262&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

8.  [8].Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021; 21: 73–82.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

9.  [9]. Rahman MdM,  Masum MdHU, Wajed S, et al. A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease 2022; 33: 1–22.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s13337-022-00755-1&link_type=DOI) 

10. [10].Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020; 20: 615–632.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

11. [11].Kent SJ, Khoury DS, Reynaldi A, et al. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? Nat Rev Immunol 2022; 22: 387–397.
    
    

12. [12].Cheng H, Peng Z, Luo W, et al. Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. Vaccines 2021; 9: 582.
    
    

13. [13].McDonald I, Murray SM, Reynolds CJ, et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines 2021; 6: 1–14.
    
    

14. [14].Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. Vaccines 2021; 9: 467.
    
    

15. [15].Sharif N, Alzahrani KJ, Ahmed SN, et al. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol 2021; 12: 714170.
    
    

16. [16].Chen J-J, Lee TH, Tian Y-C, et al. Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4: e2131749.
    
    

17. [17]. Mehrabi Nejad M-M, Moosaie F, Dehghanbanadaki H, et al. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. Eur J Med Res 2022; 27: 23.
    
    

18. [18].Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv 2022; 6: 2014–2034.
    
    

19. [19].Xu W, Tang J, Chen C, et al. Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis. J Infect 2022; 84: 722–746.
    
    

20. [20].Chou OHI, Mui J, Chung CT, et al. COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis. Clin Res Cardiol 2022; 111: 1161– 1173.
    
    

21. [21].Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1136/bmj.n71&link_type=DOI) 

22. [22].Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
    
    

23. [23].McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualising risk-of-bias assessments. Res Synth Methods 2021; 12: 55– 61.
    
    

24. [24].GRADEpro GDT: GRADEpro Guideline Development Tool, [https://www.gradepro.org/](https://www.gradepro.org/) (2022, accessed 1 June 2022).
    
    

25. [25].Olivier J, Johnson WD, Marshall GD. The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them? Ann Allergy Asthma Immunol 2008; 100: 333–337.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1081-1206(10)60595-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18450118&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000254706800008&link_type=ISI) 

26. [26].Higgins JPT, Thomas J, Chandler J (eds). Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. John Wiley & Sons, [https://blackwells.co.uk/bookshop/product/Cochrane-Handbook-for-Systematic-Reviews-of-Interventions-by-Julian-P-T-Higgins-editor-Cochrane-Collaboration-issuing-body/9781119536628](https://blackwells.co.uk/bookshop/product/Cochrane-Handbook-for-Systematic-Reviews-of-Interventions-by-Julian-P-T-Higgins-editor-Cochrane-Collaboration-issuing-body/9781119536628) (2019, accessed 22 December 2022).
    
    

27. [27].Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
    
    

28. [28].Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: A tutorial. Clin Epidemiol Glob Health 2019; 7: 192–198.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cegh.2018.05.005&link_type=DOI) 

29. [29].Keech C, Albert G, Cho I, et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 2020; 383: 2320–2332.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/nejmoa2026920&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

30. [30].Masuda T, Murakami K, Sugiura K, et al. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomised controlled trial. Vaccine 2022; 40: 3380–3388.
    
    

31. [31].Formica N, Mallory R, Albert G, et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomised placebo-controlled trial. PLOS Med 2021; 18: e1003769.
    
    

32. [32]. Duc Dang A,  Dinh Vu T,  Hai Vu H, et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine 2022; 40: 3621–3632.
    
    

33. [33].Pitisuttithum P, Luvira V, Lawpoolsri S, et al. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. eClinicalMedicine 2022; 45: 101323.
    
    

34. [34].Liao Y, Li Y, Pei R, et al. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomised, double-blind, placebo-controlled, Phase I trial. Emerg Microbes Infect 2021; 10: 1589–1597.
    
    

35. [35].Hager KJ, Pérez Marc G, Gobeil P, et al. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med 2022; 386: 2084–2096.
    
    

36. [36].Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). eClinicalMedicine 2022; 46: 101383.
    
    

37. [37].Iwata S, Sonoyama T, Kamitani A, et al. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine 2022; 40: 3721–3726.
    
    

38. [38].Meng F-Y, Gao F, Jia S-Y, et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther 2021; 6: 1–11.
    
    

39. [39].Ryzhikov AB, Б РА, Ryzhikov ЕА, et al. A single blind, placebo-controlled randomised study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russ J Infect Immun 2021; 11: 283–296.
    
    

40. [40].Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 2021; 21: 1107–1119.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(21)00127-4&link_type=DOI) 

41. [41].Guo W, Duan K, Zhang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 1/2 trial. eClinicalMedicine 2021; 38: 101010.
    
    

42. [42].Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomised Clinical Trial. JAMA 2021; 326: 35–45.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

43. [43].Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021; 21: 637–646.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(20)30942-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33485468&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

44. [44].Mohraz M, Salehi M, Tabarsi P, et al. Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open 2022; 12: e056872.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMjoiMTIvNC9lMDU2ODcyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDgvMTIvMjAyMy4wOC4xMC4yMzI5Mzk2NC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

45. [45].Pan H-X, Liu J-K, Huang B-Y, et al. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomised, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl*)* 2021; 134: 1289–1298.
    
    

46. [46].Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181–192.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

47. [47].Bueno SM, Abarca K, González PA, et al. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile. Clin Infect Dis 2021; ciab823.
    
    

48. [48].Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomised, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia. Vaccine 2021; 39: 6520–6528.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2021.09.052&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34620531&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

49. [49].Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomised, double-blinded, controlled trial. Vaccine 2021; 39: 2746–2754.
    
    

50. [50].Che Y, Liu X, Pu Y, et al. Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults. Clin Infect Dis Off Publ Infect Dis Soc Am 2021; 73: e3949–e3955.
    
    

51. [51].Zakarya K, Kutumbetov L, Orynbayev M, et al. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. eClinicalMedicine 2021; 39: 101078.
    
    

52. [52].Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 2021; 384: 1824–1835.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

53. [53].Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA 2021; 325: 1535–1544.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2021.3645&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

54. [54].Sadoff J, Gray G, Vandebosch A, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med 2022; 386: 847–860.
    
    

55. [55].Asano M, Okada H, Itoh Y, et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomised controlled phase 1/2 trial. Int J Infect Dis 2022; 114: 165–174.
    
    

56. [56].Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 2020; 396: 467–478.
    
    

57. [57].Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021; 384: 1885–1898.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2102214&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33725432&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

58. [58].Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 2020; 396: 479–488.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s0140-6736(20)31605-6&link_type=DOI) 

59. [59].Zhu F, Jin P, Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis Off Publ Infect Dis Soc Am 2022; 75: e783–e791.
    
    

60. [60].Zhu F, Zhuang C, Chu K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med 2022; 10: 749–760.
    
    

61. [61].Haranaka M, Baber J, Ogama Y, et al. A randomised study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun 2021; 12: 7105.
    
    

62. [62].Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020; 383: 2439–2450.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2027906&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

63. [63].Masuda T, Murakami K, Sugiura K, et al. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. Vaccine 2022; 40: 2044–2052.
    
    

64. [64].Chu L, McPhee R, Huang W, et al. A preliminary report of a randomised controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021; 39: 2791–2799.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2021.02.007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

65. [65].Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384: 403–416.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2035389&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

66. [66].Chen G-L, Li X-F, Dai X-H, et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 2022; 3: e193–e202.
    
    

67. [67].Shu Y-J, He J-F, Pei R-J, et al. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomised, double- blind, placebo-controlled, phase II trial. Chin Med J (Engl*)* 2021; 134: 1967–1976.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/CM9.0000000000001702&link_type=DOI) 

68. [68].Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21: 39–51.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s1473-3099(20)30831-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

69. [69].Song JY, Choi WS, Heo JY, et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. eClinicalMedicine 2022; 51: 101569.
    
    

70. [70].Mahase E. Covid-19: What we know about the BA.4 and BA.5 omicron variants. BMJ 2022; 378: o1969.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzgvYXVnMDlfNS9vMTk2OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA4LzEyLzIwMjMuMDguMTAuMjMyOTM5NjQuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

71. [71].Singh A, Khillan R, Mishra Y, et al. The safety profile of COVID-19 vaccinations in the United States. Am J Infect Control 2022; 50: 15–19.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajic.2021.10.015&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34699960&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

72. [72].Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021; 19: 173.
    
    

73. [73].Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem 2021; 36: 427–439.
    
    

74. [74].Cai C, Peng Y, Shen E, et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther 2021; 29: 2794–2805.
    
    

75. [75]. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, et al. Safety of COVID-19 vaccines. J Med Virol 2021; 93: 6588–6594.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.27214&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

76. [76].Lounis M, Rais MA, Bencherit D, et al. Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers. Front Public Health 2022; 10: 896343.
    
    

77. [77].Biswas MR, Alzubaidi MS, Shah U, et al. A Scoping Review to Find Out Worldwide COVID-19 Vaccine Hesitancy and Its Underlying Determinants. Vaccines 2021; 9: 1243.
    
    

78. [78].Khoury DS, Cromer D, Reynaldi A, et al. Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205–1211.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-021-01377-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

79. [79].Siddiqui S, Alhamdi HWS, Alghamdi HA. Recent Chronology of COVID-19 Pandemic. Front Public Health 2022; 10: 778037.
    
    

80. [80].Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 2022; 386: 1532–1546.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/nejmoa2119451&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

81. [81].Zhang Z, Mateus J, Coelho CH, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 2022; 185: 2434–2451.e17.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cell.2022.05.022&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35764089&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F12%2F2023.08.10.23293964.atom) 

82. [82].Chen Z, Zhang Y, Wang M, et al. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. Int J Biol Sci 2022; 18: 4629–4641.
    
    

83. [83].Agrati C, Carsetti R, Bordoni V, et al. The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic. Immunology 2022; 167: 287–302.
    
    

84. [84].Du Y, Chen L, Shi Y. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. Hum Vaccines Immunother 2022; 18: 2062983.
    
    

85. [85].Ghazy RM, Ashmawy R, Hamdy NA, et al. Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines 2022; 10: 350.
    
    

86. [86].Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. Epub ahead of print 2022. DOI: 10.1002/14651858.CD015477.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/14651858.CD015477&link_type=DOI)